title: Combined metallothioneins and p53 proteins expression as a prognostic marker in patients with Dukes stage B and C colorectal cancer.
abstract: Our study aimed to evaluate metallothionein and p53 expression in colorectal cancer and to correlate their combined expression with selected clinical and pathologic variables of the disease, to define their prognostic significance. Colorectal cancer specimens from 99 patients were retrospectively analyzed by immunohistochemistry for metallothionein and p53 expression. Survival curves were generated according to the Kaplan-Meier method, and univariate survival distributions were compared with the use of the log-rank test. Multivariate models were computed using Cox proportional hazards regression. This research was approved by the institutional review boards of all centers. Tumors showing concomitant high metallothionein expression and negative p53 (metallothionein(H)/p53(-)) were significantly inversely related to depth of invasion, frequency of nodal metastasis, and Dukes stage (P < .01). In univariate analysis, patients with metallothionein(H)/p53(-) phenotype showed a better overall survival (hazard ratio [HR], 2.83; P < .05) and disease-free survival (HR, 2.03; P < .05). In multivariate analysis, considering staging, metallothionein, and metallothionein + p53 variables, in 83 patients with Dukes stages B and C, metallothionein(H)/p53(-) combination was the sole factor showing an independent prognostic value for overall survival (HR, 3.88; P < .1) and disease-free survival (HR, 2.56; P < .1). In conclusion, the combined analysis of metallothionein and p53 may enhance the prognostic power of each individual marker by predicting the progression of the disease and contributing to a better identification of patients at low risk for mortality, especially for those with Dukes stage B and C colorectal cancer.
authors.affiliation: Instituto Médico Especializado Alexander Fleming, Centro de Investigaciones Oncológicas de la Fundación Cáncer, Buenos Aires, Argentina.
authors.forename: J M
authors.initials: JM
authors.lastname: Arriaga
authors.forename: I A
authors.initials: IA
authors.lastname: Bravo
authors.forename: L
authors.initials: L
authors.lastname: Bruno
authors.forename: S
authors.initials: S
authors.lastname: Morales Bayo
authors.forename: A
authors.initials: A
authors.lastname: Hannois
authors.forename: F
authors.initials: F
authors.lastname: Sanchez Loria
authors.forename: F
authors.initials: F
authors.lastname: Pairola
authors.forename: E
authors.initials: E
authors.lastname: Huertas
authors.forename: M P
authors.initials: MP
authors.lastname: Roberti
authors.forename: Y S
authors.initials: YS
authors.lastname: Rocca
authors.forename: M
authors.initials: M
authors.lastname: Aris
authors.forename: M M
authors.initials: MM
authors.lastname: Barrio
authors.forename: S
authors.initials: S
authors.lastname: Baffa Trasci
authors.forename: E M
authors.initials: EM
authors.lastname: Levy
authors.forename: J
authors.initials: J
authors.lastname: Mordoh
authors.forename: M
authors.initials: M
authors.lastname: Bianchini
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis*; D015179:Colorectal Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D018572:Disease-Free Survival; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008668:Metallothionein / Q000032:analysis* / Q000096:biosynthesis; D009367:Neoplasm Staging; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D016159:Tumor Suppressor Protein p53 / Q000032:analysis* / Q000096:biosynthesis
chemical_list: D014408:Biomarkers, Tumor; D016159:Tumor Suppressor Protein p53; D008668:Metallothionein